Exit / M&A
Hydralyte North America makes a strong debut on ASX
Hydration Pharmaceuticals, which sells Hydralyte in North America, listed on the ASX, raising $17 million at 29 cents and closing 22.4% higher. Former Swisse executives hold key roles and large stakes.